Semaglutide started in old age still extended lifespan, the checkpoint senescent cells hide behind, an Alzheimer's blood test that tells you when — and four other things worth your time this week.

Week of September 14th, 2026

The thread running through this week's research is timing: when damage gets written into a body, how long it stays invisible, and how late you can still do something about it. We lead with a Nature paper in which semaglutide, started in mice already the equivalent of sixty, extended median lifespan by roughly 12% and beat matched calorie restriction on memory and glucose control. From there: the immune checkpoint that lets senescent cells hide from the immune system that should be clearing them, the first genome-wide evidence that diet changes how fast mutations accumulate, a pooled analysis of 8,582 people showing that an Alzheimer's blood test only reads properly alongside your APOE genotype, a well-run heart failure trial that killed a popular hypothesis, a direct measurement of the mutational cost childhood chemotherapy leaves in a liver, and the identification of the stem cell behind one of the most common spine surgeries in people over sixty. Seven findings, graded honestly. Here's what's worth your attention.

1. Semaglutide Started in Old Age Still Extended Lifespan

Most longevity drugs are tested in young animals, which tells you almost nothing about the question a 60-year-old actually has, which is whether it is too late. Danica Chen's lab at UC Berkeley went at that question directly in Nature. They gave the GLP-1 receptor agonist semaglutide to 20-month-old female C57BL/6 mice, roughly a human in their early sixties, for three months. Treated animals improved on physiological function testing, showed attenuated hallmarks of aging in tissue, and shifted nutrient sensors and conserved genetic regulators of aging. Mice kept on the drug to the end of life had a median lifespan about 100 days longer than untreated controls, on the order of 12%. The critical comparison was head-to-head against matched calorie restriction: the semaglutide mice voluntarily ate about 24% less, and a separate group restricted to that same intake did about as well on lifespan. But semaglutide beat calorie restriction on exploratory drive, spatial memory, and glucose control.

Grade it as the strongest evidence yet that a drug millions of people already take acts on aging biology itself, in an animal that is not a person. The framing the authors land on is that semaglutide behaves as a calorie restriction mimetic, which is a decades-old goal of the field, and the calorie-matched arm is what makes the claim credible: much of the benefit does run through eating less, but the memory and glucose findings sit above what reduced intake explains. The caveats are real and specific. This was female mice only, in one strain, and mouse lifespan results have a long history of shrinking or vanishing on replication. There is no human lifespan trial of semaglutide, and there will not be one soon, because the trial would take decades. Nothing here changes who should be on a GLP-1. What it changes is the prior: a drug being prescribed for weight and glucose may be doing work on a deeper layer, and late is apparently not the same as too late.

Feng Y, Chen D, et al. Late-life semaglutide treatment slows ageing and extends lifespan in female mice. Nature. 2026;657(8131):469-476. DOI: 10.1038/s41586-026-10940-7. https://doi.org/10.1038/s41586-026-10940-7

2. The Immune Checkpoint Senescent Cells Hide Behind

Senolytics work by killing senescent cells, which quietly concedes the more interesting question: your immune system is supposed to clear these cells, and at some point it stops. Selim Chaib and James Kirkland at the Center for Advanced Gerotherapeutics at Cedars-Sinai, working with Mayo Clinic, the University of Osaka, and IRB Barcelona, report in Cell Metabolism that senescent cells have been using the same trick tumors use. PD-L2, the quieter sibling of the PD-L1 protein that cancer immunotherapy targets, is upregulated on isolated senescent human cells and rises with age. Old PD-L2 knockout mice accumulated fewer senescent cells than old wild-type mice, and had better insulin sensitivity and greater grip strength. Anti-PD-L2 antibody therapy restored insulin sensitivity in aged wild-type mice. Senolytic drugs preferentially removed the senescent cells expressing the most PD-L2, which ties the two approaches together.

Grade it as a mechanistic advance that reframes cellular senescence from a killing problem into an immune-evasion problem. That reframing matters because it suggests the next generation of senolytics may look like immunotherapy rather than like a drug that poisons cells directly, and because it explains persistence rather than just describing it. The evidence is mouse genetics plus antibody treatment in mice plus human cell work, with no human data at all. The obvious worry is that checkpoint blockade in oncology is famously accompanied by immune-related adverse events, and the risk calculus for a cancer patient is not the risk calculus for a healthy 65-year-old who feels fine. The reason for cautious optimism is that PD-L2 has a much more restricted expression pattern than PD-L1, so blocking it may be a narrower intervention. There is nothing to take, and there is a target worth watching.

Chaib S, Langhi Prata LGP, Suda M, et al. Blocking PD-L2 prevents senescent cell accumulation and age-related dysfunction. Cell Metabolism. 2026. DOI: 10.1016/j.cmet.2026.08.014. https://doi.org/10.1016/j.cmet.2026.08.014

3. Eating 30% Less Changed How Fast Mutations Accumulate

Genomic instability sits on every list of the hallmarks of aging and has been the one nobody could move. Mutations pile up in every cell across a life, most are harmless, and the ones that land in the wrong gene cause cancer. Marta Grońska-Pęski and Gilad Evrony at NYU Langone, with Jonathan Shoag at Case Western and the calorie-restriction cohort built by Joseph Takahashi and Carla Green at UT Southwestern, asked in Cell whether diet touches that process genome-wide. They fed mice 30% fewer calories than free feeding and used high-fidelity duplex sequencing to read mutations off single DNA molecules in bulk liver, bulk kidney, isolated hepatocytes, and cerebellar neurons. Caloric restriction reduced both substitution and insertion/deletion burdens, with liver responding more than kidney or brain. It also dialed down SBS5, the enigmatic clock-like mutational process responsible for most mutations in mammals. The surprise was where: the reduction was largest in the transcriptionally inactive regions of the genome.

Grade it as the first direct evidence that genomic integrity is a modifiable axis of aging, established in mice and not in you. The finding is mechanistically interesting precisely because of the asymmetry. If caloric restriction reduces DNA damage across the whole genome, actively transcribed regions would benefit least, because they already repair damage constantly; the quiet regions have the most to gain. The caveats are the usual ones and they bite hard here. This is mouse work, 30% restriction is a level of deprivation humans do not sustain outside of a study, and fewer mutations is not the same as fewer tumors or more years, which this study did not measure in the same animals. The practical value is not a diet prescription. It is that a hallmark previously filed under inevitable now has a dial attached to it, and the useful next question is what mediates the effect, because that is the thing you could eventually take without eating a third less food.

Grońska-Pęski M, Acosta-Rodríguez V, Srinivasa A, et al. Caloric restriction modulates genome-wide somatic mutation in mice. Cell. 2026. DOI: 10.1016/j.cell.2026.08.013. https://doi.org/10.1016/j.cell.2026.08.013

4. The Alzheimer's Blood Test Only Reads Properly Alongside Your Genotype

Plasma p-tau217 tests are now commercially available, people are ordering them, and very few of them know what a number means for their own life. Richard Mayeux's group at Columbia's Taub Institute went after exactly that in The Lancet Neurology, pooling participant-level data from seven multi-ethnic prospective cohorts in the United States, Canada, and the Dominican Republic. Of 8,873 people screened, 8,582 were analyzed, mean age 70, 65.9% female, 16.1% Black, 47.3% non-Hispanic White, and 36.7% Hispanic or other ethnic origin. Higher baseline p-tau217 was associated with prevalent cognitive impairment (odds ratio 1.77, 95% CI 1.42-2.20) and with incident impairment among the 4,569 who started cognitively normal (hazard ratio 1.41 per standard deviation, 95% CI 1.22-1.64). APOE-ε4 status changed the math substantially: the incident hazard ratio was 1.76 in carriers versus 1.26 in non-carriers. Each one-standard-deviation rise in p-tau217 was associated with a 24% shorter time to cognitive impairment in ε4 carriers, against 13% in non-carriers. Survival curves separated 3 to 4 years after the blood draw, before any symptoms appeared.

Grade it as the most immediately useful finding this week for anyone who has actually been offered one of these tests. The central message is that a p-tau217 result is not a diagnosis, it is a hazard rate, and the same number carries a meaningfully different timeline depending on a genotype most people have never checked. This is pooled observational cohort data rather than a trial, assay platforms and cut-points are not standardized across laboratories, and the outcome combines mild cognitive impairment with dementia. The largest honest limitation is not statistical: there is still no intervention proven to change the trajectory in an asymptomatic person, which is what would convert early knowledge from distressing into actionable. If you are considering the test, decide in advance what you would do with a high result, and know that the number should be interpreted with APOE rather than on its own.

Xu Y, Gunasekaran TI, Gu Y, et al. Plasma phosphorylated tau 217 concentrations, APOE genotype, and timing of cognitive impairment in individuals across diverse racial and ethnic groups: a pooled analysis of prospective cohort studies. The Lancet Neurology. 2026. DOI: 10.1016/S1474-4422(26)00313-3. https://doi.org/10.1016/S1474-4422(26)00313-3

5. A Good Heart Failure Hypothesis Died This Week, Cleanly

Heart failure with preserved ejection fraction is roughly half of all heart failure, it is the form that tracks most closely with aging and metabolic disease, and the list of treatments that actually work is embarrassingly short. The myeloperoxidase hypothesis looked strong on paper: MPO-derived oxidants reduce nitric oxide availability, stiffen cardiomyocytes, and drive coronary microvascular dysfunction and interstitial fibrosis. Lars Lund at Karolinska, Carolyn Lam in Singapore, and Sanjiv Shah at Northwestern, with AstraZeneca, tested it properly in Nature Medicine. In a multicentre, randomized, double-blind, three-arm phase 2b trial, 711 patients with ejection fraction above 40% (45% women) were randomized 1:1:1 to mitiperstat 2.5 mg, mitiperstat 5 mg, or placebo for 48 weeks. The co-primary endpoints at 16 weeks were the Kansas City Cardiomyopathy Questionnaire Total Symptom Score and 6-minute walk distance. Neither moved: a placebo-corrected difference of -1.4 points on KCCQ-TSS (95% CI -3.9 to 1.2; P = 0.29) and 3.8 metres on walk distance (95% CI -3.1 to 10.8; P = 0.28). No secondary endpoint moved either. The drug was safe apart from maculopapular rash in 3.6% versus 0.4% on placebo.

Grade it as a clean, well-powered negative trial, which is worth considerably more than it sounds. Negative results in this field usually arrive buried in a conference poster; this one arrives in a top journal with confidence intervals tight enough to essentially exclude a clinically meaningful benefit at these doses over this window. The fair counterargument is that 48 weeks of symptom and function endpoints could miss a drug that works slowly on remodeling, and KCCQ and 6-minute walk are noisy measures. But the practical read is straightforward. For HFpEF, the interventions with real evidence remain SGLT2 inhibitors, increasingly GLP-1 receptor agonists in the obesity-related phenotype, and the unglamorous work of blood pressure, weight, and exercise capacity. Oxidative stress as a stand-alone drug target has now failed one more well-designed trial, and that is a pattern worth updating on rather than explaining away.

Lund LH, Lam CSP, Pizzato PE, et al. Myeloperoxidase inhibition with mitiperstat in heart failure with preserved or mildly reduced ejection fraction: a randomized phase 2b trial. Nature Medicine. 2026. DOI: 10.1038/s41591-026-04615-z. https://doi.org/10.1038/s41591-

026-04615-z

6. Childhood Chemotherapy Leaves an Adult's Worth of Mutations in a Child's Liver

More than four in five children with cancer now survive, which has moved the field's central question from whether they live to what the treatment costs them four decades later. Anna Wenger and Sam Behjati at the Wellcome Sanger Institute, with the Francis Crick Institute, King's College Hospital, and Great Ormond Street, measured that cost directly in Science. Using duplex sequencing (NanoSeq), which detects mutations from single DNA molecules rather than inferring them from a crowd of cells, they analyzed 186 samples across a wide range of normal tissues from nine children treated with platinum chemotherapy for liver cancer, against 77 samples from children who received non-platinum treatment or none. Platinum agents raised mutation burdens in normal pediatric tissue to levels ordinarily seen in adults, averaging roughly 2,200 mutations per liver sample. The burden scaled with exposure: children given cisplatin alone carried fewer mutations than those given both cisplatin and carboplatin. The liver also carried its own tissue-specific mutational signature, absent from every other tissue. Gene-focused sequencing turned up a wide diversity of nonsynonymous variants, including known leukemogenic variants in blood.

Grade it as a definitive measurement of a cost the field could previously only infer. This is direct human tissue data rather than a model, which is rare in this space and is what gives it weight. What it does not show is that any particular survivor will develop a second cancer or liver disease; mutation burden is a risk substrate, not an outcome, and platinum chemotherapy saves lives that would otherwise be lost, which is not a close call and should not be read as one. The real implications are in two places. It strengthens the case for long-term organ-specific surveillance in childhood cancer survivors, with the liver now carrying a documented reason to be watched. And it raises the value of de-escalation research, meaning the search for equally effective regimens that write less into the genome. If you or your child received platinum chemotherapy, ongoing follow-up is not anxiety, it is arithmetic.

Wenger A, Vannier JB, Lee-Six H, et al. Extensive and differential platinum chemotherapy mutagenesis in livers of children. Science. 2026;393(6816):eady0339. DOI: 10.1126/science.ady0339. https://doi.org/10.1126/science.ady0339

7. The Stem Cell Behind One of the Most Common Spine Surgeries

Lumbar spinal stenosis is one of the leading reasons adults over sixty end up in an operating room, and the reason there is no drug for it is embarrassingly basic: nobody knew which cell was doing the damage. The ligamentum flavum thickens over decades, the spinal canal narrows, the cord and nerve roots get compressed, and the only fix on offer is surgical decompression. Matthew Greenblatt at Weill Cornell Medicine and Sravisht Iyer at the Hospital for Special Surgery closed that gap in Cell, identifying the tendon/ligament stem cell in both mice and humans. It is a Lin−Thy1.2−Sca-1−CD73+CD140α− population, present in every tendon and ligament they examined, that self-renews and sits at the apex of the tenocyte differentiation hierarchy, confirmed in vivo by somatic-variant-based lineage tracing rather than by marker inference alone. Inducing stenosis reprogrammed these cells through cell-intrinsic, calcium-signaling-dependent changes to increase their tenocyte output, which is the cellular mechanism of the ligament thickening itself.

Grade it as foundational cell biology with an unusually short line to a drug target. The reprogramming step runs through calcium and NFAT signaling, a pathway with existing pharmacology, and the authors describe it explicitly as druggable. The evidence is mouse models plus identification of the same population in human tissue, with no therapeutic candidate and no trial, so the distance between this paper and a pill that keeps a spinal canal open is measured in years and complicated by a real specificity problem: the same stem cell maintains every tendon and ligament in the body, and you do not want to shut it down everywhere. What makes it matter beyond the spine is scope. This is the progenitor for all tendon and ligament tissue, which makes it a plausible entry point into tendinopathy and the slow stiffening of connective tissue that quietly makes training harder in the second half of life.

Hu L, Sun J, Morse KW, et al. Identification of the tendon/ligament stem cell in mice and humans. Cell. 2026. DOI: 10.1016/j.cell.2026.08.018. https://doi.org/10.1016/j.cell.2026.08.018

Have a great week,

Dr. Smith and Winston

Medical disclaimer

The content above is for informational and educational purposes only and does not constitute medical, nutritional, or professional advice. It is not intended to diagnose, treat, cure, or prevent any disease and is not a substitute for personalized guidance from a licensed physician or other qualified healthcare provider. Individual needs and risks vary. Do not begin, stop, or modify any exercise regimen, dietary plan, medication (including GLP-1 receptor agonists such as semaglutide, SGLT2 inhibitors, or any chemotherapy regimen), or supplement based on this article alone. Consult your doctor first — particularly if you have or suspect a cardiovascular, metabolic, kidney, gastrointestinal, or neurological condition, take prescription medications, or are pregnant or breastfeeding. Studies summarized here vary in design and quality; preclinical and animal findings often do not translate to humans, and associations reported in observational research do not prove cause and effect.